Chengyang Zhang
Research Subjects
Chengyang Zhang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Aihua Lu
Guangdong Hengqin Xinchuangyi Biomedical Co., Ltd., Zhuhai 519000, China
1 shared publication - Kun Mi
Department of Environmental and Global Health, College of Public Health and Health Professions, University of Florida, Gainesville, FL 32611, USA; Center for Environmental and Human Toxicology, University of Florida, Gainesville, FL 32611, USA
1 shared publication - Lei Sun
MOA Laboratory of Risk Assessment for Quality and Safety of Livestock and Poultry Products, Wuhan 430070, China
1 shared publication - Lingli Huang
National Laboratory for Veterinary Drug Safety Evaluation, Huazhong Agriculture University, Wuhan, 430070, China; National Reference Laboratory of Veterinary Drug Residues (HZAU), Huazhong Agriculture University, Wuhan, 430070, China; MOA Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, Hubei, 430070, China; College of Veterinary Medicine, Huazhong Agriculture University, Wuhan, 430070, China
1 shared publication - Ru Wang
MOA Laboratory of Risk Assessment for Quality and Safety of Livestock and Poultry Products, Wuhan 430070, China
1 shared publication - Yanfei Tao
National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for the Detection of Veterinary Drug Residues, Huazhong Agricultural University, Wuhan, China
1 shared publication
Latest Publications
- Open Access
- 11 September 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (9) , 915
Postβ-Lactamase-Inhibiting Effect of Sulbactam in Combination with Ceftriaxone on Extended-Spectrum-β-Lactamase-Producing Escherichia coli
Background/Objectives: Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli poses a significant global health challenge, as it leads to antimicrobial treatment failure and is associated with elevated mortality rates. The use of β-lactam/β-lactamase inhibitor combinations offers an alternative approach for combating ESBL-producing bacteria. Ceftriaxone (CRO) and sulbactam have been coadministered in the clinical settings; however, discrepancies in their pharmacokinetics raise concerns regarding the rationality of this combination. Methods: This study was designed to investigate the postβ-lactamase inhibitor effect (PLIE) under both static and dynamic conditions, with the aim of supporting the clinical application of this combination. Results: The minimum inhibitory concentration (MIC) of CRO/SBT (2:1 ratio) against E. coli NCTC 13353 was determined to be 32/16 μg/mL. The PLIEs were determined to be −1.26, −0.57, and 0.37 h at CRO/SBT concentrations ranging from 1/2 MIC to 2 MIC, respectively. The results of CRO concentration, β-lactamase activity, blaCTX-M-15 expression, and cell morphology collectively support that SBT exerts PLIEs and protects against the antibacterial activity of CRO. In the dynamic hollow-fiber infection model, CRO monotherapy showed no inhibitory effect on E. coli, whereas CRO/SBT combination therapy rapidly eliminated SBT, achieved comparable bactericidal effects, prolonged CRO exposure, and maintained low β-lactamase activity levels. Conclusions: In conclusion, CRO/SBT exerts an inhibitory effect on enzyme-producing strains by being able to produce PLIE to maintain the inhibition of β-lactamase.
- 11 September 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (9) , 915
Open AccessPostβ-Lactamase-Inhibiting Effect of Sulbactam in Combination with Ceftriaxone on Extended-Spectrum-β-Lactamase-Producing Escherichia coli
Background/Objectives: Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli poses a significant global health challenge, as it leads to antimicrobial treatment failure and is associated with elevated mortality rates. The use of β-lactam/β-lactamase inhibitor combinations offers an alternative approach for combating ESBL-producing bacteria. Ceftriaxone (CRO) and sulbactam have been coadministered in the clinical settings; however, discrepancies in their pharmacokinetics raise concerns regarding the rationality of this combination. Methods: This study was designed to investigate the postβ-lactamase inhibitor effect (PLIE) under both static and dynamic conditions, with the aim of supporting the clinical application of this combination. Results: The minimum inhibitory concentration (MIC) of CRO/SBT (2:1 ratio) against E. coli NCTC 13353 was determined to be 32/16 μg/mL. The PLIEs were determined to be −1.26, −0.57, and 0.37 h at CRO/SBT concentrations ranging from 1/2 MIC to 2 MIC, respectively. The results of CRO concentration, β-lactamase activity, blaCTX-M-15 expression, and cell morphology collectively support that SBT exerts PLIEs and protects against the antibacterial activity of CRO. In the dynamic hollow-fiber infection model, CRO monotherapy showed no inhibitory effect on E. coli, whereas CRO/SBT combination therapy rapidly eliminated SBT, achieved comparable bactericidal effects, prolonged CRO exposure, and maintained low β-lactamase activity levels. Conclusions: In conclusion, CRO/SBT exerts an inhibitory effect on enzyme-producing strains by being able to produce PLIE to maintain the inhibition of β-lactamase.